Fundz

Indaptus Therapeutics reported raising $227,000 in an initial SEC Form D filing, from an offering of $227,000

PUBLIC · INDPDec 06, 2024

Amount Raised

$227,000

$227,000 sold, per SEC Form D (first sale Nov 22, 2024)

Round Type

Pre-Seed

New YorkHealthcare

Who else raised in Healthcare around the same time

Companies in the same sectors as Indaptus Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Outset Medical raised $3.9M (Seed) on January 3, 2025.
  • Preceptis Medical raised $2M (Seed) on December 31, 2024.
  • Northwest Biotherapeutics raised $5M (Convertible Note) on December 31, 2024.
  • Os Therapies raised $6M (Post-IPO Equity) on December 31, 2024.
  • Metabolon raised $7.5M on December 31, 2024.
  • MediView XR raised $14M on December 31, 2024.

Who to call at Indaptus Therapeutics, Inc., and when

A new round usually means Indaptus Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Indaptus Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Indaptus Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Indaptus Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Indaptus Therapeutics, Inc.

Location

3 COLUMBUS CIRCLE

New York, New York, United States

About

The Indaptus Goal is Simple: to Cure Disease With the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. Leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Indaptus Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts10 people are listed at Indaptus Therapeutics, In…. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Indaptus Therapeutics, Inc.'s next move

See what Strategic adds

Indaptus Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.